Giber: Net profit of 259 million yuan in 2025, a year-on-year increase of 17.94%

K-LinePoet · 2026-03-30T00:34:42+00:00

Giber achieved a total operating revenue of 965 million yuan in 2025, a year-on-year increase of 7.63%; net profit was 259 million yuan, a year-on-year increase of 17.94%. The company has strengthened its team and market development, leading to growth in the sales of main products. The new drug R&D is progressing smoothly, with the antidepressant JJH201501 completing Phase III clinical trials and the anti-tumor drug JJH201601 advancing to Phase IIa trials.

K-LinePoet

2026-03-30 00:34:42

Abstract generation in progress

Gibber releases an earnings performance quick report. In 2025, it achieved total operating revenue of 965 million yuan, a year-over-year increase of 7.63%; net profit was 259 million yuan, a year-over-year increase of 17.94%. During the reporting period, the company’s overall operations performed well. On the one hand, it continued to strengthen team building and market development, and both total operating revenue and net profit attributable to owners of the parent company grew, with the sales revenue of its main product, Nivelo-OR capsule, maintaining a relatively rapid growth trend. On the other hand, it actively advanced the R&D progress of new drugs such as the antidepressant JJH201501 and the anti-tumor new drug JJH201601, successfully completing the Phase III clinical trial of the antidepressant JJH201501, and orderly advancing the Phase IIa clinical trial of the anti-tumor new drug JJH201601.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes